Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Anti-CD3 Immunotoxin A-dmDT390-bisFv(UCHT1)

Known as: A-dmDT390-bisFv(UCHT1) 
A bivalent recombinant fusion protein immunotoxin derived from the anti-CD3 monoclonal antibody UCHT1 with potential antineoplastic activity. Anti… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Primary cutaneous T-cell lymphomas (CTCLs), such as mycosis fungoides and Sézary syndrome, are a rare group of non-Hodgkin… Expand
  • figure 1
  • table 1
Is this relevant?
2009
2009
e19511 Background: T cell lymphomas represent 12% of lymphoma cases in the U.S. Cytotoxic chemotherapies, radiation therapies… Expand
Is this relevant?
2008
2008
The bivalent anti-T cell immunotoxin, A-dmDT390-bisFv(UCHT1), was developed for treatment of T-cell leukemia, autoimmune diseases… Expand
Is this relevant?
2008
2008
The bivalent anti-human T cell immunotoxin A-dmDT390-bisFv(UCHT1) for treatment of patients with T cell malignancies is a single… Expand
  • table 2
  • table 4
  • table 5
  • figure 1
  • figure 2
Is this relevant?